Barrington Research reaffirmed their outperform rating on shares of HealthEquity (NASDAQ:HQY – Free Report) in a research report sent to investors on Friday morning, Benzinga reports. Barrington Research currently has a $105.00 target price on the stock.
Other analysts have also issued reports about the stock. Robert W. Baird raised their price target on shares of HealthEquity from $98.00 to $104.00 and gave the stock an outperform rating in a research report on Tuesday, June 4th. Bank of America decreased their target price on shares of HealthEquity from $105.00 to $100.00 and set a buy rating on the stock in a research report on Wednesday, September 4th. Deutsche Bank Aktiengesellschaft lifted their target price on shares of HealthEquity from $102.00 to $103.00 and gave the company a buy rating in a research report on Wednesday, September 4th. JMP Securities reiterated a market outperform rating and set a $105.00 target price on shares of HealthEquity in a research report on Wednesday, September 4th. Finally, Royal Bank of Canada reiterated an outperform rating and set a $92.00 target price on shares of HealthEquity in a research report on Wednesday, September 4th. One analyst has rated the stock with a hold rating and twelve have given a buy rating to the company’s stock. Based on data from MarketBeat, the stock has an average rating of Moderate Buy and a consensus target price of $103.83.
Read Our Latest Report on HealthEquity
HealthEquity Stock Performance
Insider Activity
In other news, Director Frank Corvino sold 7,705 shares of the stock in a transaction dated Monday, July 8th. The shares were sold at an average price of $81.89, for a total value of $630,962.45. Following the transaction, the director now directly owns 6,070 shares of the company’s stock, valued at $497,072.30. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. In related news, Director Frank Corvino sold 7,705 shares of the firm’s stock in a transaction dated Monday, July 8th. The shares were sold at an average price of $81.89, for a total transaction of $630,962.45. Following the transaction, the director now directly owns 6,070 shares of the company’s stock, valued at $497,072.30. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, Vice Chairman Stephen Neeleman sold 35,000 shares of the firm’s stock in a transaction dated Thursday, July 25th. The stock was sold at an average price of $79.86, for a total transaction of $2,795,100.00. Following the transaction, the insider now directly owns 89,769 shares in the company, valued at $7,168,952.34. The disclosure for this sale can be found here. Insiders own 2.20% of the company’s stock.
Institutional Investors Weigh In On HealthEquity
A number of hedge funds have recently made changes to their positions in the stock. Cape Investment Advisory Inc. bought a new position in HealthEquity in the 4th quarter valued at approximately $27,000. Rise Advisors LLC bought a new position in HealthEquity in the 1st quarter valued at approximately $28,000. International Assets Investment Management LLC bought a new position in HealthEquity in the 2nd quarter valued at approximately $35,000. YHB Investment Advisors Inc. bought a new position in HealthEquity in the 1st quarter valued at approximately $40,000. Finally, Fidelis Capital Partners LLC bought a new position in HealthEquity in the 1st quarter valued at approximately $42,000. 99.55% of the stock is currently owned by institutional investors and hedge funds.
HealthEquity Company Profile
HealthEquity, Inc provides technology-enabled services platforms to consumers and employers in the United States. The company offers cloud-based platforms for individuals to make health saving and spending decisions, pay healthcare bills, receive personalized benefit information, earn wellness incentives, grow their savings, and make investment choices; and health savings accounts.
Featured Stories
- Five stocks we like better than HealthEquity
- 3 Home Improvement Stocks that Can Upgrade Your Portfolio
- The Average 401k Balance by Age Explained
- Stocks with Unusual Volume: How to Find Unusual Volume Stocks in Real Time
- 3 Uranium Stocks To Gain as Microsoft Goes Nuclear to Power AI
- Comparing and Trading High PE Ratio Stocks
- Biotech Boom Ahead? Key Stocks and ETFs to Watch Now
Receive News & Ratings for HealthEquity Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for HealthEquity and related companies with MarketBeat.com's FREE daily email newsletter.